Effect of Moxibustion Intervention on Insomnia Patients

Insomnia Clinical Trial

Official title:

Effect of Moxibustion Intervention on Insomnia Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06171308
• Other study ID #: 2022-YJ14
• Status: Recruiting
• Phase: N/A
• Start date: January 1, 2023
• Est. completion date: December 31, 2025

Study information

• Verified date: October 2023
• Source: Shanghai Mental Health Center
• Contact: JING Cai, Undergraduate
• Phone: 13524000307
• Email: 1994510cj[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Type of study:clinical trial Purpose of research:To explore the efficacy and safety of moxibustion combined with Traditional Chinese and Western medicine in treating insomnia.

Describe participant population/health conditions:120 insomnia patients

Description:

Type of study:clinical trial Purpose of research:To explore the efficacy and safety of moxibustion combined with Traditional Chinese and Western medicine in treating insomnia.

Describe participant population/health conditions:120 insomnia patients The participants were enrolled according to the principle of randomization and single blindness, and the analysis was adjusted every quarter according to the research schedule. The study group was treated with traditional Chinese moxibustion and western medicine. The control group was treated with only western medicine.

Clinical evaluation of the main efficacy indicators: The score of PSQI scale was assessed. The reduction rate of PSQI scale was ≥ 25% as effective, and the difference between the two groups was compared as the basis for evaluating the main efficacy indicators. The efficacy of insomnia symptoms was evaluated by the difference of PSQI score reduction rate between groups before and after intervention.

Secondary clinical outcome measures: Quality of Life Scale (SQLS), SF-36 scale, Clinical Gross Impression Scale (CGI), adverse reaction（TESS） .

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Meet the diagnostic criteria of ICD-10 insomnia;

2. In line with the relevant diagnostic criteria of TCM syndrome differentiation of heart-spleen and deficiency type insomnia (TCM syndrome diagnosis criteria according to the 1993 Ministry of Health "Guidelines for Clinical Research on the treatment of Insomnia with new Chinese Medicine" standards: heart-spleen and deficiency: palpitation, amnesia, dizziness, poor and tired, pale face, easy to sweat, tongue, thin coat, thin pulse);

3. Pittsburgh Sleep Quality Index (PSQI) score > 7 at baseline;

4. The treatment plan used in this study is tolerable, cooperative and compliant;

5. Regardless of gender, age 18-65 years old;

6. Understand the procedure and content of the test, and voluntarily sign the informed consent;

Exclusion Criteria:

1. Participating in other clinical studies;

2. Exclude patients with serious physical diseases or diseases that may affect the evaluation of the test;

3. there is a clear risk of suicide or danger to oneself or others;

4. Exclude pregnant or lactating women, or those planning pregnancy;

5. Persons with alcohol and drug dependence within 1 year prior to screening.

Related Conditions & MeSH terms

• Insomnia
• Moxibustion
• Sleep Initiation and Maintenance Disorders

Intervention

Device:
• Traditional Chinese moxibustion apparatus
The study group was treated with traditional Chinese moxibustion and western medicine. The control group was treated with blank moxibustion and western medicine. The study group: Using the moxibustion, select specific 3 groups of acupoints. Select a group of acupuncture points every day, in the moxibustion treatment for 20 minutes, 4 weeks for a course of treatment. The control group: Using the moxibustion with blank patch, select specific 3 groups of acupoints. Select a group of acupuncture points every day, in the moxibustion treatment for 20 minutes, 4 weeks for a course of treatment. The treatment period is 4 weeks, which is a course of treatment, and the observation period is 8 weeks.

Locations

Country	Name	City	State
China	moxibustion equipment(Zhongshan Jiaxun medical equipment Co., LTD)	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Mental Health Center

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The score of PSQI	The reduction rate of PSQI scale =25% was regarded as effective, and the difference between the two groups was compared as the basis for evaluating the main therapeutic effect indicators. The efficacy of insomnia symptoms was evaluated by the difference in the reduction rate of PSQI scores between the two groups before and after the intervention.	Baseline, week two, week four, week eight
Secondary	The score of Quality of Life Scale (SQLS)	The score reduction rate was taken as the therapeutic grade standard, and the score reduction rate =[(pre-treatment score - post-treatment score) ÷ pre-treatment score]×100%. The score reduction rate after treatment was = 75% for clinical recovery, 50%-75% for obvious effect, 25%-50% for effective, and < 25% for ineffective. Total response rate = (effective + effective + cured)/total cases *100%.	Baseline, week two, week four, week eight
Secondary	The score of SF-36 scale	The score reduction rate was taken as the therapeutic grade standard, and the score reduction rate =[(pre-treatment score - post-treatment score) ÷ pre-treatment score]×100%. The score reduction rate after treatment was = 75% for clinical recovery, 50%-75% for obvious effect, 25%-50% for effective, and < 25% for ineffective. Total response rate = (effective + effective + cured)/total cases *100%.	Baseline, week two, week four, week eight
Secondary	The score of Clinical Gross Impression Scale (CGI)	The score reduction rate was taken as the therapeutic grade standard, and the score reduction rate =[(pre-treatment score - post-treatment score) ÷ pre-treatment score]×100%. The score reduction rate after treatment was = 75% for clinical recovery, 50%-75% for obvious effect, 25%-50% for effective, and < 25% for ineffective. Total response rate = (effective + effective + cured)/total cases *100%.	Baseline, week two, week four, week eight
Secondary	adverse reaction(TESS)evaluation	The score reduction rate was taken as the therapeutic grade standard, and the score reduction rate =[(pre-treatment score - post-treatment score) ÷ pre-treatment score]×100%. The score reduction rate after treatment was = 75% for clinical recovery, 50%-75% for obvious effect, 25%-50% for effective, and < 25% for ineffective. Total response rate = (effective + effective + cured)/total cases *100%.	Baseline, week two, week four, week eight